Literature DB >> 17079357

Heteroduplex analysis for the three common HFE variants: methodology, reliability and analysis of over 5000 requests for testing.

Jeanne Kingston1, Derrick Bowen, Marion Sweeney, Susan Lawless, Helen Jackson, Mark Worwood.   

Abstract

OBJECTIVE: To describe the analysis of over 5300 patient samples for the HFE genotype.
METHODS: Blood samples received from hospitals in England, Wales and Ireland were analysed with a single, multiplex PCR using heteroduplex generators for the C282Y, H63D and S65C variants of the HFE gene. PCR products labelled with fluorescent dyes were analysed by capillary electrophoresis. Genotype frequencies were analysed according to the reasons given for testing.
RESULTS: Analysis of 400 samples sent in duplicate revealed one error that was associated with reporting rather than the methodology. Of 5327 samples received, 1122 were for family testing, 2470 for diagnostic testing and in 1735 cases no reason was given. Overall, homozygosity for C282Y was found in 14% of samples received for family testing and in 16% of the remaining samples. Clinical indications such as "liver disease" were of little predictive value for homozygosity for C282Y, but this increased if a raised serum ferritin concentration or transferrin saturation was indicated. When the diagnosis was iron overload, 39% of subjects tested were homozygous for C282Y. Compound heterozygosity (C282Y/H63D) was more frequent than in the general population but the frequency was not further increased in subjects for whom there was a diagnosis of iron overload. The frequencies of heterozygosity for H63D or S65C and homozygosity for H63D were not significantly increased in any group compared with the general population frequency.
CONCLUSION: These results demonstrate the reliability of the methodology and confirm the difficulty of identifying genetic haemochromatosis purely on the basis of clinical suspicion that haemochromatosis may be responsible for liver disease, diabetes or arthritis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17079357      PMCID: PMC2095483          DOI: 10.1136/jcp.2006.042010

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  27 in total

1.  Geography of HFE C282Y and H63D mutations.

Authors:  A T Merryweather-Clarke; J J Pointon; A M Jouanolle; J Rochette; K J Robson
Journal:  Genet Test       Date:  2000

Review 2.  HFE Mutations as risk factors in disease.

Authors:  Mark Worwood
Journal:  Best Pract Res Clin Haematol       Date:  2002-06       Impact factor: 3.020

3.  HFE mutations in an inflammatory arthritis population.

Authors:  G Willis; D G I Scott; B A Jennings; K Smith; M Bukhari; J Z Wimperis
Journal:  Rheumatology (Oxford)       Date:  2002-02       Impact factor: 7.580

4.  Reverse cascade screening of newborns for hereditary haemochromatosis: a model for other late onset diseases?

Authors:  E Cadet; D Capron; M Gallet; M-L Omanga-Léké; H Boutignon; C Julier; K J H Robson; J Rochette
Journal:  J Med Genet       Date:  2005-05       Impact factor: 6.318

5.  A rare case of a patient heterozygous for the hemochromatosis mutation C282Y and homozygous for H63D.

Authors:  G Lucotte; T Champenois; O Sémonin
Journal:  Blood Cells Mol Dis       Date:  2001 Sep-Oct       Impact factor: 3.039

6.  HFE mutations, iron deficiency and overload in 10,500 blood donors.

Authors:  H A Jackson; K Carter; C Darke; M G Guttridge; D Ravine; R D Hutton; J A Napier; M Worwood
Journal:  Br J Haematol       Date:  2001-08       Impact factor: 6.998

7.  HFE gene mutation (C282Y) and phenotypic expression among a hospitalised population in a high prevalence area of haemochromatosis.

Authors:  S Distante; J P Berg; K Lande; E Haug; H Bell
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

8.  Penetrance of 845G--> A (C282Y) HFE hereditary haemochromatosis mutation in the USA.

Authors:  Ernest Beutler; Vincent J Felitti; James A Koziol; Ngoc J Ho; Terri Gelbart
Journal:  Lancet       Date:  2002-01-19       Impact factor: 79.321

9.  Hemochromatosis mutations C282Y and H63D in 'cis' phase.

Authors:  L G Best; P E Harris; E L Spriggs
Journal:  Clin Genet       Date:  2001-07       Impact factor: 4.438

10.  Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons.

Authors:  A Asberg; K Hveem; K Thorstensen; E Ellekjter; K Kannelønning; U Fjøsne; T B Halvorsen; H B Smethurst; E Sagen; K S Bjerve
Journal:  Scand J Gastroenterol       Date:  2001-10       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.